Precisemab Biotech Co., Ltd.

PSM101 is a preclinical anti-EGFR antibody powered by PrecisemAb's proprietary Universal Antibody Lock, designed to
enable conditional activation, reduce
on-target toxicity, and maintain efficacy.
Its tumor-selective activity has been validated in in vitro and in vivo models.

• Clinical Trial Collaboration
• Out-Licensing
• Collaborative R&D
• Co-Development